Background: Thrombolysis using intravenous (IV) tissue plasminogen activator (tPA) is one of few evidence-based acute stroke treatments, yet achieving high rates of IV tPA delivery has been problematic. The 4.5-h treatment window, the complexity of determining eligibility criteria and the availability of expertise and required resources may impact on treatment rates, with barriers encountered at the levels of the individual clinician, the social context and the health system itself. The review aimed to describe health system factors associated with higher rates of IV tPA administration for ischemic stroke and to identify whether system-focussed interventions increased tPA rates for ischemic stroke. Methods: Published original English-langua...
Background Intravenous thrombolytic therapy (IVT) with tissue plasminogen activator for acute ischem...
Intravenous recombinant tissue plasminogen activator is a highly effective treatment for acute ische...
Background: Intravenous thrombolytic therapy after ischaemic stroke significantly reduces mortality ...
What is known and Objective: Thrombolysis using intravenous tissue plasminogen activator (tPA) is th...
Background and Purpose-Thrombolysis with intravenous recombinant tissue plasminogen activator is an ...
Background: Stroke is a leading cause of death and disability internationally. One of the three effe...
BACKGROUND: Stroke is a leading cause of death and disability internationally. One of the three effe...
Background and Purpose: Timely intravenous (IV) thrombolysis for acute ischemic stroke is associated...
Background—We sought to determine if intravenous tissue plasminogen activator (IV tPA) use for acute...
Background: Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is licensed f...
BACKGROUND: Although recombinant tissue plasminogen activator (tPA) improves outcomes from ischemic...
Although a wide range of strategies have been established to improve intravenous tissue plasminogen ...
In the Netherlands, as in most Western countries, stroke is a major contributor to the total burden ...
BACKGROUND: Although recombinant tissue plasminogen activator (tPA) improves outcomes from ischemic ...
Abstract Background Although the efficacy of tissue p...
Background Intravenous thrombolytic therapy (IVT) with tissue plasminogen activator for acute ischem...
Intravenous recombinant tissue plasminogen activator is a highly effective treatment for acute ische...
Background: Intravenous thrombolytic therapy after ischaemic stroke significantly reduces mortality ...
What is known and Objective: Thrombolysis using intravenous tissue plasminogen activator (tPA) is th...
Background and Purpose-Thrombolysis with intravenous recombinant tissue plasminogen activator is an ...
Background: Stroke is a leading cause of death and disability internationally. One of the three effe...
BACKGROUND: Stroke is a leading cause of death and disability internationally. One of the three effe...
Background and Purpose: Timely intravenous (IV) thrombolysis for acute ischemic stroke is associated...
Background—We sought to determine if intravenous tissue plasminogen activator (IV tPA) use for acute...
Background: Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is licensed f...
BACKGROUND: Although recombinant tissue plasminogen activator (tPA) improves outcomes from ischemic...
Although a wide range of strategies have been established to improve intravenous tissue plasminogen ...
In the Netherlands, as in most Western countries, stroke is a major contributor to the total burden ...
BACKGROUND: Although recombinant tissue plasminogen activator (tPA) improves outcomes from ischemic ...
Abstract Background Although the efficacy of tissue p...
Background Intravenous thrombolytic therapy (IVT) with tissue plasminogen activator for acute ischem...
Intravenous recombinant tissue plasminogen activator is a highly effective treatment for acute ische...
Background: Intravenous thrombolytic therapy after ischaemic stroke significantly reduces mortality ...